SiBone (NASDAQ:SIBN) CEO Sells $78,538.46 in Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 3,923 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $20.02, for a total value of $78,538.46. Following the completion of the transaction, the chief executive officer owned 317,463 shares in the company, valued at $6,355,609.26. This represents a 1.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Laura Francis also recently made the following trade(s):

• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Stock Performance

SIBN stock opened at $19.96 on Monday. The firm has a 50 day simple moving average of $17.49 and a 200 day simple moving average of $15.32. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The stock has a market cap of $885.21 million, a P/E ratio of -58.71 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The firm had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. Research analysts anticipate that SiBone will post -0.4 earnings per share for the current fiscal year.

Institutional Trading of SiBone

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SIBN. Hussman Strategic Advisors Inc. bought a new position in SiBone during the 4th quarter valued at about $1,656,000. UBS Group AG increased its holdings in shares of SiBone by 570.2% during the fourth quarter. UBS Group AG now owns 104,731 shares of the company’s stock worth $2,065,000 after buying an additional 89,105 shares in the last quarter. Impax Asset Management Group plc increased its holdings in shares of SiBone by 17.1% during the fourth quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock worth $23,664,000 after buying an additional 175,000 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after acquiring an additional 182,465 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of SiBone in the fourth quarter valued at approximately $838,000. Institutional investors own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SIBN. Truist Financial reissued a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. UBS Group increased their price target on SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. TD Cowen lifted their price target on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SiBone presently has an average rating of “Moderate Buy” and an average price target of $24.17.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.